Alx oncology presents first evorpacept combination data with an antibody-drug conjugate from phase 1 aspen-07 clinical trial in patients with advanced bladder cancer

South san francisco, calif., june 02, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today presented data from its phase 1 aspen-07 clinical trial in a poster presentation (abstract #4575) at the 2024 american society of cancer oncology (“asco”) annual meeting being held in chicago from may 31-june 4, 2024. these findings represent the first evorpacept combination data with an adc from aspen-07's ongoing, open-label, single-arm, clinical trial of evorpacept in combination with padcev (enfortumab vedotin or “ev”) in patients with locally advanced or metastatic urothelial cancer (“la/m uc”). evorpacept is a cd47 blocker with an inactivated fc effector domain that is designed to minimize associated toxicity.
ALXO Ratings Summary
ALXO Quant Ranking